Boston Therapeutics, Inc.
Get Full AccessDescription
- Boston Therapeutics is a clinical stage pharmaceutical company focused on developing drugs to treat diabetes and inflammatory diseases. The Company is focused on developing novel formations and to leverage development partnerships to apply its complex carbohydrate chemistry design in other indications and may seek to enter into licensing, co-marketing, or co-development agreements for parts or all-of-the-world in order to avail the company of the marketing expertise of one or more seasoned marketing and/or pharmaceutical companies. The Companys highly experienced drug development leadership provides the Company with a significant competitive advantage in designing highly efficient clinical programs to deliver valuable products in areas of high unmet medical needs.Boston Therapeutics intends to realize its business objectives by leveraging its expertise in complex carbohydrate chemistry. A core part of the Company strategy relied upon creating safe and efficacious drug formulations that can be administered as standalone therapies or in combination with existing medications. Product development plans for BTI320 is currently in Phase II. BTI320 works non-systematically in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose. This action reduces the amount of glucose available for absorption into the bloodstream. IPOXYN is a carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death, and treat hypoxis conditions such as diabetic foot ulcers and other vascular complications of diabetes. Hypoxia is a condition in which cells lack sufficient oxygen supply to support metabolic function. The IPOXYN carbohydrate molecule contains oxygen rechargeable iron which picks up oxygen in the lungs, is 5,000 times smaller than a red blood cell (RBC), and can reach hypoxic tissue more effectively than RBC. The Company OXYFEX, a veterinary analog to IPOXYN.
-
Headquarters:354 Merrimack Street , Lawrence, Massachusetts, United States
More -
Phone Number: +1 603-935-9799
-
Website: https://www.bostonti.com
-
Employees:7
-
Revenue:$1 - 10M
-
Legal Name:Boston Therapeutics, Inc.
-
Boston Therapeutics, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 541713 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Boston Therapeutics, Inc.
-
Where are Boston Therapeutics, Inc.'s Headquarters?
Boston Therapeutics, Inc.'s Headquarters are in 354 Merrimack Street ,Lawrence,Massachusetts,United States
-
What is Boston Therapeutics, Inc.'s phone number?
Boston Therapeutics, Inc.'s phone number is +1 603-935-9799
-
What is Boston Therapeutics, Inc.'s official website?
Boston Therapeutics, Inc.'s official website is https://www.bostonti.com
-
What is Boston Therapeutics, Inc.'s Revenue?
Boston Therapeutics, Inc.'s revenue is $1 - 10M
-
What is Boston Therapeutics, Inc.'s NAICS code?
Boston Therapeutics, Inc.'s NAICS code is 541713
-
How many employees are working in Boston Therapeutics, Inc.
Boston Therapeutics, Inc. has 7 employees
-
What is Boston Therapeutics, Inc.'s Industry?
Boston Therapeutics, Inc. is in the industry of Biotechnology
-
Who is Boston Therapeutics, Inc.'s Consulting Director Of Finance?
Boston Therapeutics, Inc.'s Consulting Director Of Finance is Stephen Spanos